Varsha Gupta
Varsha Gupta, Encinitas, CA US
Patent application number | Description | Published |
---|---|---|
20110065692 | THERAPEUTIC PYRAZOLONAPHTHYRIDINE DERIVATIVES - The invention provides a novel chemical series of formula I, as well as methods of use thereof for binding to the benzodiazepine site of the GABA | 03-17-2011 |
20110065693 | THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES - The invention provides a novel chemical series of formula I, as well as methods of use thereof for binding to the benzodiazepine site of the GABA | 03-17-2011 |
20110071140 | THERAPEUTIC PYRAZOLOQUINOLINE UREA DERIVATIVES - The invention provides a novel chemical series of formula I, as well as methods of use thereof for binding to the benzodiazepine site of the GABA | 03-24-2011 |
20120095016 | THERAPEUTIC 5,6,5-TRICYCLIC ANALOGS - The invention provides a novel chemical series of formula I, as well as methods of use thereof for binding to the benzodiazepine site of the GABA | 04-19-2012 |
20140275548 | SUBSTITUTED NAPHTHYRIDINE AND QUINOLINE COMPOUNDS AS MAO INHIBITORS - The invention provides a chemical entity of Formula (I) | 09-18-2014 |
20140315944 | SUBSTITUTED NAPHTHYRIDINE AND QUINOLINE COMPOUNDS AS MAO INHIBITORS - The invention provides a chemical entity of Formula (I) | 10-23-2014 |
Varsha Gupta, Singapore SG
Patent application number | Description | Published |
---|---|---|
20100021035 | METHOD FOR IDENTIFYING A PATHOLOGICAL REGION OF A SCAN, SUCH AS AN ISCHEMIC STROKE REGION OF AN MRI SCAN - A method for identifying a pathological region of a scan (such as a stroke region within a MRI DWI volume scan) is proposed. A region of the scan which is likely to contain pathological tissue (e.g. infracted tissue) is identified by obtaining a parameter which, for a given slice, or portion of a slice, characterises the distribution of the intensity of pixels, e.g. the relative proportion of high intensity pixels. In a first case, such a parameter is used to identify those slices of a volume scan which are likely to include infarction. In a second case, such a parameter (hemisphere parameter) is obtained for each of the left- and right-hemispheres of a brain, to estimate which hemisphere contains the stroke. In either case, the parameter may be calculated based on ranges, percentiles and functions of the percentiles of the intensity distribution. These ranges, percentiles and functions of the percentiles are not pre-defined but are selected to maximise sensitivity. | 01-28-2010 |
20100040264 | REGISTERING BRAIN IMAGES BY ALIGNING REFERENCE ELLIPSES - In a method of registering three-dimensional brain images, a reference slice for a midsagittal plane of each image is constructed. The reference slice comprises image points forming a cortical edge. Edge points are selected from these image points such that an ellipse fit to the edge points approximates the cortical edge. The reference ellipse in each image that fits the edge points is determined. The images are registered in a same coordinate system such that the reference ellipses in the images are aligned with one another. | 02-18-2010 |
20100231216 | Segmenting infarct in diffusion-weighted imaging volume | 09-16-2010 |
20100290689 | DISCRIMINATING INFARCTS FROM ARTIFACTS IN MRI SCAN DATA - An algorithm is proposed to eliminate from MRI images pixels which have been incorrectly identified as corresponding to infarct material. A first technique is to eliminate identified regions which are determined to be similar to the region of the scan which corresponds to the identified region reflected in the mid-sagittal plane (MSP) of the brain. A second technique is to eliminate regions which are determined not to have corresponding identified regions in one or more of the other scans. The combination of two techniques enhances the confidence in the decision of whether a hyperintense region is an infarct or artifact. | 11-18-2010 |
20120099779 | METHOD AND SYSTEM FOR SEGMENTING A BRAIN IMAGE - A method is proposed for segmenting a brain image into a CSF region, a WM region and a GM region. An upper limit for the intensity values of a CSF region in the image is estimated such that the points of the image having an intensity less than this upper limit include a subset of the points which form a spatially connected group and which have a peaked intensity distribution. In other words, the invention exploits both the expected spatial distribution and expected intensity distribution of the CSF region. This makes it possible for the method to provide reliable discrimination of the CSF region even in CT images with poor image quality. Various methods are proposed for using the upper limit, and for improving the segmentation accuracy. | 04-26-2012 |
20120246181 | METHOD FOR CONSTRUCTION AND USE OF A PROBABILISTIC ATLAS FOR DIAGNOSIS AND PREDICTION OF A MEDICAL OUTCOME - Medical scan data, such as brain scan data, from a plurality of patients suffering from a medical condition such as a stroke is used to construct a probabilistic atlas. A first portion of the atlas indicates, for each location, the corresponding likelihood of a medical abnormality (such as a lesion) associated with the medical condition being present at that location. A second portion of the atlas includes, for each location and each of one or more parameters, corresponding parameter data indicative of the values taken by the parameter for those patients suffering from the medical abnormality at the corresponding location. The probabilistic map can be used to extract outcome data from a scan obtained from a new subject, such as by locating a medical abnormality within the scan of the subject, and obtaining the outcome data using the corresponding locations in the probabilistic map. | 09-27-2012 |
Varsha Gupta, Matrix SG
Patent application number | Description | Published |
---|---|---|
20100172553 | LOCALIZATION OF BRAIN LANDMARKS SUCH AS THE ANTERIOR AND POSTERIOR COMMISSURES BASED ON GEOMETRICAL FITTING - A method of estimating the location of the anterior and posterior commissures in a brain scan image is proposed. Firstly, a geometrical object is constructed using points on a brain scan image of an individual which are on the surface of the brain, such as an ellipse fitting the cerebral surface of a sagittal image of the mid-sagittal plane, or an adjacent sagittal plane. The locations on the MSP of the AC and PC landmarks (and optionally other landmarks) are estimated using the five parameters which define the ellipse, plus numerical values obtained in advance from statistical analysis of other individuals. | 07-08-2010 |
Varsha Gupta, San Diego, CA US
Patent application number | Description | Published |
---|---|---|
20080306048 | THERAPEUTIC PYRAZOLOQUINOLINE UREA DERIVATIVES - The invention provides a novel chemical series of formula I, as well as methods of use thereof for binding to the benzodiazepine site of the GABA | 12-11-2008 |
20080306049 | THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES - The invention provides a novel chemical series of formula I, as well as methods of use thereof for binding to the benzodiazepine site of the GABA | 12-11-2008 |
20090005365 | THERAPEUTIC PYRAZOLONAPHTHYRIDINE DERIVATIVES - The invention provides a novel chemical series of formula I, as well as methods of use thereof for binding to the benzodiazepine site of the GABA | 01-01-2009 |
Varsha Gupta, Lucknow IN
Patent application number | Description | Published |
---|---|---|
20110305754 | CONTROLLED RELEASE MICRO-CAPSULE FOR OSTEOGENIC ACTION - The present invention relates to a microcapsule for controlled release of flavanoid compound and a process for preparation thereof. The microcapsule comprising a core particle consisting of a calcium salt, Pluronic F68 [poly (ethylene oxide-co-polypropylene co-polypropylene oxide), block poly oxyethylene-polypropylene block copolymer], loaded with a flavanoid compound, the resulting core particle having a plurality of alternate layers of cationic and anionic polyelectrolytes adsorbed thereon and an outer layer formed by a bile salt, wherein the flavanoid is ranging between 10 to 96% by weight. | 12-15-2011 |
20130338193 | CHIRAL 1-(4-METHYLPHENYLMETHYL)-5-OXO--PYRROLIDINE-2-CARBOXAMIDES AS INHIBITORS OF COLLAGEN INDUCED PLATELET ACTIVATION AND ADHESION - Chiral 1-(4-methylphenylmethyl)-5-oxo-{N-[(3-t-butoxycarbonyl-aminomethyl)]-piperidin-1-yl}-pyrrolidine-2-carboxamides as inhibitors of collagen induced platelet activation and adhesion The present invention provides chiral (2S)-1-(4-methyl-phenylmethyl)-5-oxo-(3S)-{N-[(3-t butoxycarbonyl aminomethyl)]-piperidin-1-yl}-pyrrolidine-2-carboxamide, and (2S)-1-(4-methylphenylmethyl)-5-oxo-(3R)-{N-[(3-t-butoxycarbonyl amino methyl)]-piperidin-1-yl}-pyrrolidine-2-carboxamide of formula 6 and 7 respectively. The present invention also relates to use of these moieties as inhibitors of collagen induced platelet adhesion and aggregation mediated through collagen receptors. The present invention provides a process for preparation of chiral carboxamides of formula 6 and 7 using the process which has advantage to avoid any racemization at the a-carboxylic center, during N-alkylation. The reagent LiHMDS is used at low temperatures to furnish methyl N-(p methylphenylmethyl)lpyroglutamate in good chiral purity. | 12-19-2013 |